Physiology and pathophysiology of the blood-brain barrier: P-glycoprotein and occludin trafficking as therapeutic targets to optimize central nervous system drug delivery

Journal of Investigative Medicine

Volumn 60, Issue 8, 2012, Pages 1131-1140

  McCaffrey, Gwen ^a,b   Davis, Thomas P ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Blood brain barrier; CNS drug delivery; Occluding; Oxidative stress; P glycoprotein; Peripheral inflammatory pain; Protein trafficking; Protein protein interaction

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN; OCCLUDIN; PSYCHOTROPIC AGENT; STEROID HORMONE; TEMPOL; XENOBIOTIC AGENT;

BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG TRANSPORT; ENDOTHELIUM CELL; MICROVASCULATURE; PATHOPHYSIOLOGY; PROTEIN FUNCTION; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; TIGHT JUNCTION;

ANIMALS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; OCCLUDIN; P-GLYCOPROTEIN; PROTEIN BINDING; PROTEIN TRANSPORT;

EID: 85006154199     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e318276de79     Document Type: Conference Paper

References (171)

1. Zlokovic BV, Apuzzo ML. Strategies to circumvent vascular barriers of the central nervous system. Neurosurgery. 1998;43(4):877-878.
2. Zlokovic BV. Cerebrovascular permeability to peptides: manipulations of transport systems at the blood-brain barrier. Pharm Res. 1995;12(10):1395-1406.
3. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57(2):173-185.
4. Abbott NJ, Patabendige AA, Dolman DE, et al. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1):13-25.
5. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7(1):41-53.
6. Pardridge WM. Drug targeting to the brain. Pharm Res. 2007;24(9):1733-1744.
7. el-Bacha RS, Minn A. Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain. Cell Mol Biol (Noisy-le-grand). 1999;45(1):15-23.
8. Ronaldson PT, Davis TP. Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery. Ther Deliv. 2011;2(8):1015-1041.
9. Petty MA, Lo EH. Junctional complexes of the blood-brain barrier: permeability changes in neuroinflammation. Prog Neurobiol. 2002;68(5):311-323.
10. Chodobski A, Zink BJ, Szmydynger-Chodobska J. Blood-brain barrier pathophysiology in traumatic brain injury. Transl Stroke Res. 2011;2(4):492-516.
11. Ronaldson PT, Davis TP. Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke. Curr Pharm Des. 2012;18(25):3624-3644.
12. Vangilder RL, Rosen CL, Barr TL, et al. Targeting the neurovascular unit for treatment of neurological disorders. Pharmacol Ther. 2011;130(3):239-247.
13. Banks WA, Erickson MA. The blood-brain barrier and immune function and dysfunction. Neurobiol Dis. 2010;37(1):26-32.
14. Stanimirovic DB, Friedman A. Pathophysiology of the neurovascular unit: disease cause or consequence? J Cereb Blood Flow Metab. 2012;32(7):1207-1221.
15. Hom S, Fleegal MA, Egleton RD, et al. Comparative changes in the blood-brain barrier and cerebral infarction of SHR and WKY rats. Am J Physiol Regul Integr Comp Physiol. 2007;292(5): R1881-R1892.
16. Sandoval KE, Witt KA. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol Dis. 2008;32(2):200-219.
17. Fraser PA. The role of free radical generation in increasing cerebrovascular permeability. Free Radic Biol Med. 2011;51(5):967-977.
18. Banks WA. Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier. Adv Drug Deliv Rev. 2012;64(7):629-639.
19. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 2011;12(12):723-738.
20. Palmer AM. The role of the blood brain barrier in neurodegenerative disorders and their treatment. J Alzheimers Dis. 2011;24(4):643-656.
21. Humpel C. Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease? Exp Gerontol. 2011;46(4):225-232.
22. Bartels AL. Blood-brain barrier P-glycoprotein function in neurodegenerative disease. Curr Pharm Des. 2011; 17(26):2771-2777.
23. Sivanandam TM, Thakur MK. Traumatic brain injury: a risk factor for Alzheimer's disease. Neurosci Biobehav Rev. 2012;36(5):1376-1381.
24. Nguyen JH. Blood-brain barrier in acute liver failure. Neurochem Int. 2012;60(7):676-683.
25. Miller E. Multiple sclerosis. Adv Exp Med Biol. 2012;724:222-238.
26. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57(2):178-201.
27. van Sorge NM, Doran KS. Defense at the border: the blood-brain barrier versus bacterial foreigners. Future Microbiol. 2012;7(3):383-394.
28. Mook-Kanamori BB, Geldhoff M, van der Poll T, et al. Pathogenesis and pathophysiology of pneumococcal meningitis. Clin Microbiol Rev. 2011;24(3):557-591.
29. Coisne C, Engelhardt B. Tight junctions in brain barriers during central nervous system inflammation. Antioxid Redox Signal. 2011;15(5):1285-1303.
30. Miller F, Afonso PV, Gessain A, et al. Blood-brain barrier and retroviral infections. Virulence. 2012;3(2):222-229.
31. Strazza M, Pirrone V, Wigdahl B, et al. Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. Brain Res. 2011;1399:96-115.
32. Banks WA. The dam breaks: disruption of the blood-brain barrier in diabetes mellitus. Am J Physiol Heart Circ Physiol. 2006;291(6):H2595-H2596.
33. Wu KC, Pan HJ, Yin HS, et al. Change in P-glycoprotein and caveolin protein expression in brain striatum capillaries in New Zealand obese mice with type 2 diabetes. Life Sci. 2009; 85(23-26):775-781.
34. Hawkins BT, Lundeen TF, Norwood KM, et al. Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia. 2007;50(1):202-211.
35. De Klerk OL, Bosker FJ, Luurtsema G, et al. The role of P-glycoprotein in psychiatric disorders: a reliable guard of the brain? Cent Nerv Syst Agents Med Chem. 2011;11(3):197-209.
36. Renia L, Wu Howland S, Claser C, et al. Cerebral malaria: mysteries at the blood-brain barrier. Virulence. 2012;3(2).
37. Nag S, Kapadia A, Stewart DJ. Review: molecular pathogenesis of blood-brain barrier breakdown in acute brain injury. Neuropathol Appl Neurobiol. 2011;37(1):3-23.
38. Chen Y, Huang W. Non-impact, blast-induced mild TBI and PTSD: concepts and caveats. Brain Inj. 2011;25(7-8):641-650.
39. Helmy A, De Simoni MG, Guilfoyle MR, et al. Cytokines and innate inflammation in the pathogenesis of human traumatic brain injury. Prog Neurobiol. 2011;95(3):352-372.
40. Pop V, Badaut J. A neurovascular perspective for long-term changes after brain trauma. Transl Stroke Res. 2011;2(4):533-545.
41. Frontczak-Baniewicz M, Chrapusta SJ, Sulejczak D. Long-term consequences of surgical brain injury-characteristics of the neurovascular unit and formation and demise of the glial scar in a rat model. Folia Neuropathol. 2011;49(3):204-218.
42. Beggs S, Liu XJ, Kwan C, et al. Peripheral nerve injury and TRPV1-expressing primary afferent C-fibers cause opening of the blood-brain barrier. Mol Pain. 2010;6:74.
43. Nico B, Ribatti D. Morphofunctional aspects of the blood-brain barrier. Curr Drug Metab. 2012;13(1):50-60.
44. Kesari S. Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments. Semin Oncol. 2011;38(suppl 4):S2-S10.
45. Agarwal S, Hartz AM, Elmquist WF, et al. Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des. 2011;17(26):2793-2802.
46. Aronica E, Sisodiya SM, Gorter JA. Cerebral expression of drug transporters in epilepsy. Adv Drug Deliv Rev. 2012;64(10):919-929.
47. Potschka H. Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies? Epilepsia. 2010;51(8):1333-1347.
48. Hartz AM, Notenboom S, Bauer B. Signaling to P-glycoprotein-a new therapeutic target to treat drug-resistant epilepsy? Drug News Perspect. 2009;22(7):393-397.
49. Lazarowski A, Czornyj L, Lubienieki F, et al. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia. 2007;48(suppl 5):140-149.
50. Wolka AM, Huber JD, Davis TP. Pain and the blood-brain barrier: obstacles to drug delivery. Adv Drug Deliv Rev. 2003;55(8):987-1006.
51. Neuwelt EA, Bauer B, Fahlke C, et al. Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci. 2011;12(3):169-182.
52. Mae M, Armulik A, Betsholtz C. Getting to know the cast-cellular interactions and signaling at the neurovascular unit. Curr Pharm Des. 2011;17(26):2750-2754.
53. Hung MC, Link W. Protein localization in disease and therapy. J Cell Sci. 2011;124(pt 20):3381-3392.
54. Miller DS, Bauer B, Hartz AM. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev. 2008;60(2):196-209.
55. Miller DS. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci. 2010;31(6):246-254.
56. Sharom FJ. The P-glycoprotein multidrug transporter. Essays Biochem. 2011;50(1):161-178.
57. Roberts LM, Black DS, Raman C, et al. Subcellular localization of transporters along the rat blood-brain barrier and blood-cerebral-spinal fluid barrier by in vivo biotinylation. Neuroscience. 2008;155(2):423-438.
58. Bendayan R, Ronaldson PT, Gingras D, et al. In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J Histochem Cytochem. 2006;54(10):1159-1167.
59. Virgintino D, Robertson D, Errede M, et al. Expression of P-glycoprotein in human cerebral cortex microvessels. J Histochem Cytochem. 2002;50(12):1671-1676.
60. Sun J, He ZG, Cheng G, et al. Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit. 2004;10(1):RA5-RA14.
61. Ueno M, Nakagawa T, Wu B, et al. Transporters in the brain endothelial barrier. Curr Med Chem. 2010;17(12):1125-1138.
62. Potschka H. Targeting regulation of ABC efflux transporters in brain diseases: a novel therapeutic approach. Pharmacol Ther. 2010;125(1):118-127.
63. Hartz AM, Bauer B. Regulation of ABC transporters at the blood-brain barrier: new targets for CNS therapy. Mol Interv. 2010;10(5):293-304.
64. Hodges LM, Markova SM, Chinn LW, et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2011;21(3):152-161.
65. Palmeira A, Sousa E, Vasconcelos MH, et al. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem. 2012;19(13):1946-2025.
66. Kaye SB. Reversal of drug resistance in ovarian cancer: where do we go from here? J Clin Oncol. 2008;26(16):2616-2618.
67. Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219-234.
68. Fletcher JI, Haber M, Henderson MJ, et al. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer. 2010;10(2):147-156.
69. Kannan P, John C, Zoghbi SS, et al. Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther. 2009;86(4):368-377.
70. Choo EF, Kurnik D, Muszkat M, et al. Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier. J Pharmacol Exp Ther. 2006;317(3):1012-1018.
71. Bauer B, Hartz AM, Fricker G, et al. Modulation of P-glycoprotein transport function at the blood-brain barrier. Exp Biol Med (Maywood). 2005;230(2):118-127.
72. Hawkins BT, Rigor RR, Miller DS. Rapid loss of blood-brain barrier P-glycoprotein activity through transporter internalization demonstrated using a novel in situ proteolysis protection assay. J Cereb Blood Flow Metab. 2010;30(9):1593-1597.
73. Mahringer A, Ott M, Reimold I, et al. The ABC of the blood-brain barrier-regulation of drug efflux pumps. Curr Pharm Des. 2011;17(26):2762-2770.
74. Seelbach MJ, Brooks TA, Egleton RD, et al. Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P-glycoprotein. J Neurochem. 2007;102(5):1677-1690.
75. Fujita I, Okumura T, Sakakibara A, et al. Involvement of inflammation in severe post-operative pain demonstrated by pre-surgical and post-surgical treatment with piroxicam and ketorolac. J Pharm Pharmacol. 2012;64(5):747-755.
76. Costantini R, Affaitati G, Fabrizio A, et al. Controlling pain in the post-operative setting. Int J Clin Pharmacol Ther. 2011;49(2):116-127.
77. Brennan TJ. Pathophysiology of postoperative pain. Pain. 2011; 152(3 suppl):S33-S40.
78. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A. 1989;86(2):695-698.
79. Wang JS, Taylor R, Ruan Y, et al. Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology. 2004;29(3):551-557.
80. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77(4):491-502.
81. Fu D, Arias IM. Intracellular trafficking of P-glycoprotein. Int J Biochem Cell Biol. 2012;44(3):461-464.
82. Porcelli L, Lemos C, Peters GJ, et al. Intracellular trafficking of MDR transporters and relevance of SNPs. Curr Top Med Chem. 2009;9(2):197-208.
83. Jodoin J, Demeule M, Fenart L, et al. P-glycoprotein in blood-brain barrier endothelial cells: interaction and oligomerization with caveolins. J Neurochem. 2003;87(4):1010-1023.
84. Lajoie P, Goetz JG, Dennis JW, et al. Lattices, rafts, and scaffolds: domain regulation of receptor signaling at the plasma membrane. J Cell Biol. 2009;185(3):381-385.
85. Demeule M, Jodoin J, Gingras D, et al. P-glycoprotein is localized in caveolae in resistant cells and in brain capillaries. FEBS Lett. 2000;466(2-3):219-224.
86. Guo Z, Zhu J, Zhao L, et al. Expression and clinical significance of multidrug resistance proteins in brain tumors. J Exp Clin Cancer Res. 2010;29:122.
87. Barakat S, Turcotte S, Demeule M, et al. Regulation of brain endothelial cells migration and angiogenesis by P-glycoprotein/caveolin-1 interaction. Biochem Biophys Res Commun. 2008;372(3):440-446.
88. Barakat S, Demeule M, Pilorget A, et al. Modulation of P-glycoprotein function by caveolin-1 phosphorylation. J Neurochem. 2007;101(1):1-8.
89. McCaffrey G, Staatz WD, Sanchez-Covarrubias L, et al. P-glycoprotein trafficking at the blood-brain barrier altered by peripheral inflammatory hyperalgesia. J Neurochem. 2012;122(5):962-975.
90. Feldman GJ, Mullin JM, Ryan MP. Occludin: structure, function and regulation. Adv Drug Deliv Rev. 2005;57(6):883-917.
91. Dobrogowska DH, Vorbrodt AW. Immunogold localization of tight junctional proteins in normal and osmotically-affected rat blood-brain barrier. J Mol Histol. 2004;35(5):529-539.
92. Brooks TA, Hawkins BT, Huber JD, et al. Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations. Am J Physiol Heart Circ Physiol. 2005;289(2):H738-H743.
93. Huber JD, Hau VS, Borg L, et al. Blood-brain barrier tight junctions are altered during a 72-h exposure to lambda-carrageenan-induced inflammatory pain. Am J Physiol Heart Circ Physiol. 2002;283(4):H1531-H1537.
94. Huber JD, Witt KA, Hom S, et al. Inflammatory pain alters blood-brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol. 2001;280(3):H1241-H1248.
95. Lochhead JJ, McCaffrey G, Sanchez-Covarrubias L, et al. Tempol modulates changes in xenobiotic permeability and occludin oligomeric assemblies at the blood-brain barrier during inflammatory pain. Am J Physiol Heart Circ Physiol. 2012;302(3):H582-H593.
96. McCaffrey G, Seelbach MJ, Staatz WD, et al. Occludin oligomeric assembly at tight junctions of the blood-brain barrier is disrupted by peripheral inflammatory hyperalgesia. J Neurochem. 2008;106(6):2395-2409.
97. Hau VS, Huber JD, Campos CR, et al. Effect of lambda-carrageenan-induced inflammatory pain on brain uptake of codeine and antinociception. Brain Res. 2004;1018(2):257-264.
98. Xie R, Hammarlund-Udenaes M. Blood-brain barrier equilibration of codeine in rats studied with microdialysis. Pharm Res. 1998;15(4):570-575.
99. Bradbury MW, Patlak CS, Oldendorf WH. Analysis of brain uptake and loss or radiotracers after intracarotid injection. Am J Physiol. 1975;229(4):1110- 1115.
100. Gordh T, Sharma HS. Chronic spinal nerve ligation induces microvascular permeability disturbances, astrocytic reaction, and structural changes in the rat spinal cord. Acta Neurochir Suppl. 2006;96:335-340.
101. Cummins PM. Occludin: one protein, many forms. Mol Cell Biol. 2012;32(2):242-250.
102. Harhaj NS, Antonetti DA. Regulation of tight junctions and loss of barrier function in pathophysiology. Int J Biochem Cell Biol. 2004;36(7):1206-1237.
103. Blasig IE, Bellmann C, Cording J, et al. Occludin protein family: oxidative stress and reducing conditions. Antioxid Redox Signal. 2011;15(5):1195-1219.
104. Tsukita S, Furuse M, Itoh M. Structural and signalling molecules come together at tight junctions. Curr Opin Cell Biol. 1999;11(5):628-633.
105. Tsukita S, Furuse M, Itoh M. Molecular dissection of tight junctions. Cell Struct Funct. 1996;21(5):381-385.
106. Blasig IE, Winkler L, Lassowski B, et al. On the self-association potential of transmembrane tight junction proteins. Cell Mol Life Sci. 2006;63(4):505-514.
107. Walter JK, Castro V, Voss M, et al. Redox-sensitivity of the dimerization of occludin. Cell Mol Life Sci. 2009;66(22):3655-3662.
108. Walter JK, Rueckert C, Voss M, et al. The oligomerization of the coiled coil-domain of occludin is redox sensitive. Ann N Y Acad Sci. 2009;1165:19-27.
109. Yaffe Y, Shepshelovitch J, Nevo I, et al. The MARVEL transmembrane motif of occludin mediates oligomerization and targeting to the basolateral surface in epithelia. J Cell Sci. 2012;125 (Pt 15):3545-3556.
110. Raleigh DR, Marchiando AM, Zhang Y, et al. Tight junction-associated MARVEL proteins marveld3, tricellulin, and occludin have distinct but overlapping functions. Mol Biol Cell. 2010;21(7):1200-1213.
111. Furuse M, Itoh M, Hirase T, et al. Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions. J Cell Biol. 1994;127(6 pt 1):1617-1626.
112. Fanning AS, Little BP, Rahner C, et al. The unique-5 and -6 motifs of ZO-1 regulate tight junction strand localization and scaffolding properties. Mol Biol Cell. 2007;18(3):721-731.
113. Dorfel MJ, Huber O. Modulation of tight junction structure and function by kinases and phosphatases targeting occludin. J Biomed Biotechnol. 2012;2012:807356.
114. Barrios-Rodiles M, Brown KR, Ozdamar B, et al. High-throughput mapping of a dynamic signaling network in mammalian cells. Science. 2005;307(5715):1621- 1625.
115. Ozdamar B, Bose R, Barrios-Rodiles M, et al. Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science. 2005;307(5715):1603-1609.
116. Nusrat A, Parkos CA, Verkade P, et al. Tight junctions are membrane microdomains. J Cell Sci. 2000;113:(pt 10):1771-1781.
117. Morimoto S, Nishimura N, Terai T, et al. Rab13 mediates the continuous endocytic recycling of occludin to the cell surface. J Biol Chem. 2005;280(3):2220-2228.
118. Traweger A, Fang D, Liu YC, et al. The tight junction-specific protein occludin is a functional target of the E3 ubiquitin-protein ligase itch. J Biol Chem. 2002;277(12):10201-10208.
119. Murakami T, Felinski EA, Antonetti DA. Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability. J Biol Chem. 2009;284(31):21036-21046.
120. Mitic LL, Van Itallie CM, Anderson JM. Molecular physiology and pathophysiology of tight junctions I. Tight junction structure and function: lessons from mutant animals and proteins. Am J Physiol Gastrointest Liver Physiol. 2000;279(2):G250-G254.
121. Fujimoto K. Freeze-fracture replica electron microscopy combined with SDS digestion for cytochemical labeling of integral membrane proteins. Application to the immunogold labeling of intercellular junctional complexes. J Cell Sci. 1995;108(pt 11):3443-3449.
122. Shivers RR, Betz AL, Goldstein GW. Isolated rat brain capillaries possess intact, structurally complex, interendothelial tight junctions; freeze-fracture verification of tight junction integrity. Brain Res. 1984;324(2):313-322.
123. Macdonald JL, Pike LJ. A simplified method for the preparation of detergent-free lipid rafts. J Lipid Res. 2005;46(5):1061-1067.
124. McCaffrey G, Staatz WD, Quigley CA, et al. Tight junctions contain oligomeric protein assembly critical for maintaining blood-brain barrier integrity in vivo. J Neurochem. 2007;103(6):2540-2555.
125. Hua VB, Chang AB, Tchieu JH, et al. Sequence and phylogenetic analyses of 4 TMS junctional proteins of animals: connexins, innexins, claudins and occludins. J Membr Biol. 2003;194(1):59-76.
126. McCaffrey G, Willis CL, Staatz WD, et al. Occludin oligomeric assemblies at tight junctions of the blood-brain barrier are altered by hypoxia and reoxygenation stress. J Neurochem. 2009;110(1):58-71.
127. Lochhead JJ, McCaffrey G, Quigley CE, et al. Oxidative stress increases blood-brain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation. J Cereb Blood Flow Metab. 2010;30(9):1625-1636.
128. Davis JR, Kakar M, Lim CS. Controlling protein compartmentalization to overcome disease. Pharm Res. 2007;24(1):17-27.
129. Gonnord P, Blouin CM, Lamaze C. Membrane trafficking and signaling: two sides of the same coin. Semin Cell Dev Biol. 2012;23(2):154-164.
130. De Matteis MA, Luini A. Mendelian disorders of membrane trafficking. N Engl J Med. 2011;365(10):927-938.
131. Kondapaka SB, Singh SS, Dasmahapatra GP, et al. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther. 2003;2(11):1093-1103.
132. Richardson PG, Eng C, Kolesar J, et al. Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012;8(5):623-633.
133. Sun W, Modak S. Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine. Onco Targets Ther. 2012;5:21-29.
134. Whistler JL. Examining the role of mu opioid receptor endocytosis in the beneficial and side-effects of prolonged opioid use: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend. 2012.
135. Georgoussi Z, Georganta EM, Milligan G. The other side of opioid receptor signalling: regulation by protein-protein interaction. Curr Drug Targets. 2012;13(1):80-102.
136. Arttamangkul S, Lau EK, Lu HW, et al. Desensitization and trafficking of mu-opioid receptors in locus ceruleus neurons: modulation by kinases. Mol Pharmacol. 2012;81(3):348-355.
137. van Rijn RM, Whistler JL, Waldhoer M. Opioid-receptorheteromer-specific trafficking and pharmacology. Curr Opin Pharmacol. 2010;10(1):73-79.
138. Henley JM, Barker EA, Glebov OO. Routes, destinations and delays: recent advances in AMPA receptor trafficking. Trends Neurosci. 2011;34(5):258-268.
139. Jones AK, Buckingham SD, Sattelle DB. Proteins interacting with nicotinic acetylcholine receptors: expanding functional and therapeutic horizons. Trends Pharmacol Sci. 2010;31(10):455-462.
140. Mao LM, Guo ML, Jin DZ, et al. Post-translational modification biology of glutamate receptors and drug addiction. Front Neuroanat. 2011;5:19.
141. Mukherjee S, Tessema M, Wandinger-Ness A. Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function. Circ Res. 2006;98(6):743-756.
142. Smith TH, Sim-Selley LJ, Selley DE. Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? Br J Pharmacol. 2010;160(3):454-466.
143. Bunnett NW, Cottrell GS. Trafficking and signaling of G protein-coupled receptors in the nervous system: implications for disease and therapy. CNS Neurol Disord Drug Targets. 2010;9(5):539-556.
144. Xu ZQ, Zhang X, Scott L. Regulation of G protein-coupled receptor trafficking. Acta Physiol (Oxf). 2007;190(1):39-45.
145. Fei H, Grygoruk A, Brooks ES, et al. Trafficking of vesicular neurotransmitter transporters. Traffic. 2008;9(9):1425-1436.
146. Lise S, Buchan D, Pontil M, et al. Predictions of hot spot residues at protein-protein interfaces using support vector machines. PLoS One. 2011;6(2):e16774.
147. Fink, A., Sal-Man N, Gerber D, et al. Transmembrane domains interactions within the membrane milieu: principles, advances and challenges. Biochim Biophys Acta. 2012;1818(4):974-983.
148. Vazquez A. Protein interaction networks. In: Alzate O (Ed.) Neuroproteomics. Boca Raton (FL): CRC Press; 2010. Chapter 8. Available from: http://www.ncbi.nlm.nih.gov/books/NBK56024/. Accessed October 17, 2012
149. Davis FP, Sali A. The overlap of small molecule and protein binding sites within families of protein structures. PLoS Comput Biol. 2010;6(2):e1000668.
150. Rajasekaran S. Computational techniques for motif search. Front Biosci. 2009;14:5052-5065.
151. Zeytuni N, Zarivach R. Structural and functional discussion of the tetra-trico-peptide repeat, a protein interaction module. Structure. 2012;20(3):397-405.
152. Koes DR, Camacho CJ. Pocket Query: protein-protein interaction inhibitor starting points from protein-protein interaction structure. Nucleic Acids Res. 2012;40(Web Server issue):W387-W392.
153. Koes DR, Camacho CJ. Small-molecule inhibitor starting points learned from protein-protein interaction inhibitor structure. Bioinformatics. 2012;28(6):784-791.
154. Arkin MR, Whitty A. The road less traveled: modulating signal transduction enzymes by inhibiting their protein-protein interactions. Curr Opin Chem Biol. 2009;13(3):284-290.
155. Strauss HM, Keller S. Pharmacological interference with protein-protein interactions mediated by coiled-coil motifs. Handb Exp Pharmacol. 2008;(186):461-482.
156. Dietz GP, Bahr M. Synthesis of cell-penetrating peptides and their application in neurobiology. Methods Mol Biol. 2007;399:181-198.
157. Bolhassani A. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim Biophys Acta. 2011;1816(2):232-246.
158. Zhao TX, Martinko AJ, Le VH, et al. Development of agents that modulate protein-protein interactions in membranes. Curr Pharm Des. 2010;16(9):1055-1062.
159. Jubb H, Higueruelo AP, Winter A, et al. Structural biology and drug discovery for protein-protein interactions. Trends Pharmacol Sci. 2012;33(5):241-248.
160. von Kleist L, Haucke V. At the crossroads of chemistry and cell biology: inhibiting membrane traffic by small molecules. Traffic. 2012;13(4):495-504.
161. Mason JM. Design and development of peptides and peptide mimetics as antagonists for therapeutic intervention. Future Med Chem. 2010;2(12):1813-1822.
162. Rajadhyaksha M, Boyden T, Liras J, et al. Current advances in delivery of biotherapeutics across the blood-brain barrier. Curr Drug Discov Technol. 2011;8(2):87-101.
163. Bellavance MA, Blanchette M, Fortin D. Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS J. 2008;10(1):166-177.
164. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther. 2004;104(1):29-45.
165. Krol S. Challenges in drug delivery to the brain: nature is against us. J Control Release. 2012 May 17 [E-pub ahead of print].
166. Orthmann A, Fichtner I, Zeisig R. Improving the transport of chemotherapeutic drugs across the blood-brain barrier. Expert Rev Clin Pharmacol. 2011;4(4):477-490.
167. Chen Y, Liu L. Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev. 2012;64(7):640-665.
168. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012 August 29 [E-pub ahead of print].
169. Battaglia L, Gallarate M. Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv. 2012;9(5):497-508.
170. Rollerova E, Scsukova S, Jurcovicova J, et al. Polymeric nanoparticles-targeted drug delivery systems for treatment of CNS disorders and their possible endocrine disrupting activities. Endocr Regul. 2011;45(1):49-60.
171. Craparo EF, Bondi ML, Pitarresi G, et al. Nanoparticulate systems for drug delivery and targeting to the central nervous system. CNS Neurosci Ther. 2011;17(6):670-677.